CR20150149A - Proteínas de fusión para el tratamiento de un síndrome metabólico - Google Patents

Proteínas de fusión para el tratamiento de un síndrome metabólico

Info

Publication number
CR20150149A
CR20150149A CR20150149A CR20150149A CR20150149A CR 20150149 A CR20150149 A CR 20150149A CR 20150149 A CR20150149 A CR 20150149A CR 20150149 A CR20150149 A CR 20150149A CR 20150149 A CR20150149 A CR 20150149A
Authority
CR
Costa Rica
Prior art keywords
treatment
fusion proteins
metabolic syndrome
fusion protein
adiposity
Prior art date
Application number
CR20150149A
Other languages
English (en)
Inventor
Oliver Boscheinen
Matthias Dreyer
Paul Habermann
Hans-Ludwig Schaefer
Mark Sommerfeld
Thomas Langer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46888349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150149(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20150149A publication Critical patent/CR20150149A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una proteína de fusión que comprende al menos un compuesto de FGF-21 (factor 21 de crecimiento de fibroblastos) y al menos un agonista de GLP-1R (receptor del péptido 1 similar a glucagón) así como a composiciones farmacéuticas, usos médicos y métodos de tratamiento que implican la proteína de fusión, particularmente en el campo de diabetes, dislipidemia, obesidad y/o adiposidad.
CR20150149A 2012-09-07 2015-03-19 Proteínas de fusión para el tratamiento de un síndrome metabólico CR20150149A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306072 2012-09-07
PCT/EP2013/068239 WO2014037373A1 (en) 2012-09-07 2013-09-04 Fusion proteins for treating a metabolic syndrome

Publications (1)

Publication Number Publication Date
CR20150149A true CR20150149A (es) 2015-05-29

Family

ID=46888349

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150149A CR20150149A (es) 2012-09-07 2015-03-19 Proteínas de fusión para el tratamiento de un síndrome metabólico

Country Status (25)

Country Link
US (3) US20140073563A1 (es)
EP (1) EP2892919A1 (es)
JP (1) JP2015533483A (es)
KR (1) KR20150043505A (es)
CN (1) CN104736558A (es)
AR (1) AR092456A1 (es)
AU (1) AU2013311777B2 (es)
BR (1) BR112015004734A2 (es)
CA (1) CA2880929A1 (es)
CL (1) CL2015000379A1 (es)
CR (1) CR20150149A (es)
DO (1) DOP2015000020A (es)
EA (1) EA201590525A1 (es)
GT (1) GT201500049A (es)
HK (1) HK1207097A1 (es)
IL (1) IL237032A0 (es)
MA (1) MA37963A1 (es)
MX (1) MX2015002985A (es)
PE (1) PE20150648A1 (es)
PH (1) PH12015500194A1 (es)
SG (1) SG11201500682WA (es)
TN (1) TN2015000053A1 (es)
TW (1) TW201414750A (es)
UY (1) UY35018A (es)
WO (1) WO2014037373A1 (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
EP3125921B1 (en) 2014-03-11 2020-07-08 Novartis AG Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CA3194562C (en) * 2014-07-29 2026-03-17 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine-ursodeoxycholic salt, method of preparation and application therof
WO2016065106A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
BR112017008157A2 (pt) 2014-10-24 2017-12-19 Bristol Myers Squibb Co polipeptídeos de fgf-21 modificados e usos dos mesmos
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
HRP20191292T1 (hr) * 2014-12-23 2019-10-18 Novo Nordisk A/S Derivati fgf21 i njihova upotreba
CN105801705B (zh) * 2014-12-31 2019-05-24 天境生物科技(上海)有限公司 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
WO2017024182A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
MY195199A (en) 2016-01-13 2023-01-11 Novo Nordisk As EGF(A) Analogues with Fatty Acid Substituents
BR112018071972A2 (pt) * 2016-04-29 2019-02-26 Defensin Therapeutics Aps métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos.
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN107759696A (zh) * 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
EP3515928B1 (en) 2016-09-23 2026-01-28 Duke University Unstructured non-repetitive polypeptides having lcst behavior
BR112019012693A2 (pt) * 2016-12-22 2019-11-19 Sanofi combinações de composto de fgf21/agonista do glp-1r com razão de atividade otimizada
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
KR102781241B1 (ko) 2017-01-17 2025-03-14 암젠 인크 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
CN108440668A (zh) * 2017-02-16 2018-08-24 瑞阳(苏州)生物科技有限公司 Fgf21与igf-1的融合蛋白及其应用
ES3014984T3 (en) * 2017-03-14 2025-04-28 Sunshine Lake Pharma Co Ltd Dual-target fusion proteins comprising the fc portion of an immunoglobulin
MX2019012331A (es) 2017-04-21 2020-01-23 Yuhan Corp Metodo para producir proteinas de doble funcion y sus derivados.
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
MX2019013919A (es) 2017-06-20 2020-01-21 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS
AR112760A1 (es) 2017-07-19 2019-12-11 Novo Nordisk As Compuestos bifuncionales que comprenden un análogo de glp-1 y un análogo de egf(a)
JP7239566B2 (ja) 2017-09-22 2023-03-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
CA3082076A1 (en) * 2017-11-06 2019-05-09 Thena Biotech S.r.l. Fusion-proteins based on human ferritin and protease-cleavable peptides and their use as chemotherapeutics carriers
CN115109166B (zh) * 2017-11-24 2025-07-18 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN111518770B (zh) * 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
CN111601613A (zh) 2017-12-22 2020-08-28 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
CN113603794B (zh) * 2018-01-11 2024-01-16 安源医药科技（上海）有限公司 用于调节血糖和脂质的增效型双功能蛋白
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
US11679143B2 (en) * 2018-02-08 2023-06-20 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
EP3788343B1 (en) 2018-04-30 2024-03-27 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
US20210275643A1 (en) * 2018-06-21 2021-09-09 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
WO2020051541A1 (en) 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CN113735977A (zh) * 2020-05-28 2021-12-03 江苏康缘瑞翱生物医药科技有限公司 rhFGF21融合蛋白、编码其的多核苷酸、包含其组合物及其用途
US12054551B2 (en) 2020-07-02 2024-08-06 Sanofi FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides
JP2023540663A (ja) * 2020-07-02 2023-09-26 サノフイ Ｇｌｐ－１ｒアゴニスト／ｆｇｆ２１融合タンパク質
US20230357346A1 (en) * 2020-07-10 2023-11-09 Gi Innovation, Inc. Fusion protein including glucagon-like peptide-1 and interleukin-1 receptor antagonist and use thereof
WO2022117044A1 (en) * 2020-12-03 2022-06-09 Sunshine Lake Pharma Co., Ltd. Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof
TW202423476A (zh) * 2021-03-23 2024-06-16 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
CN113150172B (zh) * 2021-04-28 2023-09-22 中国药科大学 Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用
US20240245791A1 (en) * 2021-06-02 2024-07-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for localization of growth factors
KR20240034235A (ko) * 2021-07-14 2024-03-13 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 대사 장애를 위한 융합 폴리펩타이드
CN113583142A (zh) * 2021-08-20 2021-11-02 赣江中药创新中心 双靶点融合蛋白、编码基因、载体或宿主细胞及其应用与表达和纯化方法
US20240383959A1 (en) * 2021-09-09 2024-11-21 Northwestern University Cell-free methods and compositions comprising tagless therapeutic hormones
KR20250075642A (ko) 2022-09-21 2025-05-28 리제너론 파아마슈티컬스, 인크. 비만, 당뇨병 및 간 기능 장애를 치료하는 방법
WO2024097875A1 (en) * 2022-11-02 2024-05-10 Shattuck Labs, Inc. Fusion proteins for the treatment of nonalcoholic steatohepatitis
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN115991793A (zh) * 2023-01-16 2023-04-21 上海民为生物技术有限公司 具有多重活性的融合蛋白及其应用
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
PE20252745A1 (es) * 2023-03-30 2025-12-05 Novo Nordisk As Compuestos de fusion y usos de estos
WO2024233999A2 (en) 2023-05-11 2024-11-14 University Hospitals Cleveland Medical Center Anxiolytic therapy
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
CN117801124A (zh) * 2024-02-29 2024-04-02 天津凯莱英生物科技有限公司 利西那肽前体的融合蛋白及其应用
CN117801125B (zh) * 2024-02-29 2024-05-24 天津凯莱英生物科技有限公司 艾塞那肽前体的融合蛋白及其应用
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
CN119241721A (zh) * 2024-09-25 2025-01-03 郑州大学 一种重组人abd-irisin蛋白及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03219892A (ja) * 1990-01-24 1991-09-27 Kyowa Hakko Kogyo Co Ltd タンパク質の製造法
GB9725556D0 (en) * 1997-12-03 1998-02-04 Ciba Geigy Ag Organic compounds
BR0007414A (pt) * 1999-01-07 2001-10-16 Lexigen Pharm Corp Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
CN1993378A (zh) * 2004-08-03 2007-07-04 转化技术制药公司 Rage融合蛋白及使用方法
DK1919514T3 (da) * 2005-07-05 2012-08-20 Univ California Polynucleotider kodende for isoprenoid-modificerende enzymer og fremgangsmåder til anvendelse deraf
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
AR063384A1 (es) * 2006-10-25 2009-01-28 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
MX2010001684A (es) * 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
CN108530543B (zh) * 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
WO2011047180A1 (en) * 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
US20110312881A1 (en) * 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
EP2359843A1 (en) * 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2658979B1 (en) * 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US9676857B2 (en) * 2012-03-16 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble engineered monomeric Fc

Also Published As

Publication number Publication date
EP2892919A1 (en) 2015-07-15
HK1207097A1 (en) 2016-01-22
AR092456A1 (es) 2015-04-22
CN104736558A (zh) 2015-06-24
TW201414750A (zh) 2014-04-16
US20140073563A1 (en) 2014-03-13
MA37963A1 (fr) 2018-06-29
TN2015000053A1 (en) 2016-06-29
PH12015500194A1 (en) 2015-04-20
DOP2015000020A (es) 2015-04-15
GT201500049A (es) 2016-02-15
US20190085043A1 (en) 2019-03-21
CA2880929A1 (en) 2014-03-13
CL2015000379A1 (es) 2015-06-05
EA201590525A1 (ru) 2015-07-30
UY35018A (es) 2014-03-31
SG11201500682WA (en) 2015-02-27
AU2013311777B2 (en) 2018-02-01
MX2015002985A (es) 2015-06-22
BR112015004734A2 (pt) 2017-11-21
US20160194371A1 (en) 2016-07-07
AU2013311777A1 (en) 2015-03-19
IL237032A0 (en) 2015-03-31
WO2014037373A1 (en) 2014-03-13
PE20150648A1 (es) 2015-05-25
JP2015533483A (ja) 2015-11-26
KR20150043505A (ko) 2015-04-22

Similar Documents

Publication Publication Date Title
DOP2015000020A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
ECSP14030742A (es) Proteínas del factor 21 de crecimiento del fibroblasto
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
MX2019007584A (es) Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada.
AR092076A1 (es) Proteinas homodimericas
CL2012002031A1 (es) Composición farmacéutica que contiene al menos un compuesto fgf-21 (factor de crecimiento de fibroblastos 21) y al menos un agonista del glp-1r (receptor del péptido 1 similar al glucagón); y su uso para preparara un medicamento para el tratamiento de al menos un síndrome metabólico y/o aterosclerosis en un paciente.
AR087973A1 (es) Variantes del factor 21 del crecimiento de fibroblastos
EA201492064A1 (ru) Варианты фактора роста фибробластов 21
AR092925A1 (es) Derivados de exendina-4 como agonistas duales de glp1 / glucagon
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
CL2014002556A1 (es) Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.
UA114792C2 (uk) Коагоніст глюкагонового рецептора/glp-1-рецептора